Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... ... ... - Spasticity Affects a Significant Number of Post-Stroke ... , , ...
... Robbins & Myers, Inc. (NYSE: RBN ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of ...
Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... allege the blood thinner caused patients to suffer uncontrollable ... in U.S. courts, Bernstein Liebhard LLP reports. According to ... August 14th in U.S. District Court, Easter District of ... who died due to a bleeding event that was ...
(Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
(Date:8/21/2014)... Steven Reinberg HealthDay Reporter ... of U.S. teens using sunscreen dropped nearly 12 percent in ... same time period, the number of teens using indoor tanning ... sunscreen increase the risk of skin cancers, including deadly melanomas, ... the overall percentage of teens who reported wearing sunscreen, from ...
(Date:8/21/2014)... August 21, 2014. Researchers have published a study ... of patients with motor complete spinal cord injury ... functioning at discharge and follow-up among patients with ... print on August 2 by the Archives ... Findings included small but significant differences in self-care ...
(Date:8/21/2014)... August 21, 2014 CarePoint Health ... Amish P. Patel, MD, and Sujoy Menon, MD, ... Dr. Patel and Dr. Menon to the community. ... of diagnostic imaging services to patients in Hudson ... Center, Christ Hospital and Hoboken University Medical Center. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:Two Top Radiologists Join CarePoint Health 2
... Survey finds children and their children are ... March 27 (HealthDay News) -- Alzheimer,s care in the ... suggests. , Three in five so-called "sandwich" caregivers who ... said their children help with care duties, ranging from ...
... Unveiling a Secure, Convenient Solution to Identify Blood ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a leader ... a proud sponsor at the spring,2008 AABB Conference ... association formerly known as the American Association of,Blood ...
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... free dental screening, DALLAS, March 27 ... Computer Services, Inc. (ACS) will,sponsor free dental education ... 28. The event will be held for pupils ... in Dallas, starting at 9:00 a.m., The ...
... study ... participants, MINNEAPOLIS, ... Minnesota Cancer Center and ClearWay Minnesota(SM) found that,since the Freedom to ... significantly reduced exposure to a,tobacco-specific cancer causing chemical., The study ...
... Up, and Changes Lives, One Smile at ... a Time via Operation Smile Partnership, CINCINNATI, March 26 ... to host an upcoming award show,Samantha Harris knows firsthand the importance ... has partnered with Oral-B Satin,Floss to not only show people how ...
Cached Medicine News:Health News:With Alzheimer's, It Takes a Family 2Health News:With Alzheimer's, It Takes a Family 3Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 2Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 3Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:ACS Expands National Dental Outreach Program to Dallas 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 3Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 2Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 3
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: